News | March 09, 2023
Lonza upgrades powder characterization capabilities at Tampa
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Subscribe To Our Newsletter & Stay Updated
